Tara Myers, MD
Endocrinology, Diabetes & Metabolism · Carmel, INNPI 1598936056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 28.5% of the total. Reporting peaked in 2019 at $1,152 and has fallen 98.4% since, to $18 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IN, where the typical reported total is $1,569.
Across 151 payments — averaging $12.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$546
- AstraZeneca$211
- Mannkind Corporation$151
- Lilly USA, LLC$111
- Amgen$107
- Sanofi-aventis U.S. LLC$103
- plus $685 from 20 others
What the payments were for
- Food & beverage$1,83096%
- Education$231%
- Gifts$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $546 |
| AstraZeneca(2 entities) | 11 | $211 |
| Mannkind Corporation | 7 | $151 |
| Lilly USA, LLC | 6 | $111 |
| Amgen(2 entities) | 7 | $107 |
| Sanofi-aventis U.S. LLC | 7 | $103 |
| Insulet Corporation | 5 | $70 |
| Merck | 5 | $70 |
| Tandem Diabetes Care, Inc. | 3 | $63 |
| Medtronic(2 entities) | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 4 | $50 |
| Antares Pharma, Inc. | 3 | $47 |
| Companion Medical, Inc. | 3 | $39 |
| Abbott | 2 | $38 |
| Amarin Pharma, Inc. | 3 | $37 |
| AbbVie | 2 | $32 |
| Corcept Therapeutics | 2 | $25 |
| Senseonics, Incorporated | 1 | $25 |
| Cequr Corporation | 1 | $25 |
| Shire North American Group Inc | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Vivus LLC | 1 | $5 |
How this compares
$1,912 in reported general payments places this provider in the 50th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $131,943 |
| MounjaroTirzepatide | 68 | $94,588 |
| JardianceEmpagliflozin | 80 | $83,751 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 45 | $57,223 |
| FarxigaDapagliflozin Propanediol | 62 | $49,115 |
| TrulicityDulaglutide | 30 | $43,644 |
| RybelsusSemaglutide | 18 | $34,612 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $27,781 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $21,799 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $19,962 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $16,953 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $13,319 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $12,010 |
| Novolog FlexpenInsulin Aspart | 36 | $11,042 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $10,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $546 | $223,778143 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $111 | $148,057127 claims |
| AstraZenecaFarxiga | $211 | $49,11562 claims |
| AbbVieSynthroid | $32 | $7,25176 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $17 | $4,937226 claims |
| IBSA Pharma Inc.Tirosint | $15 | $2,26416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Carmel
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.